Celularity Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CELU research report →
Companywww.celularity.com
Celularity Inc. , a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking.
- CEO
- Robert Joseph Hariri
- IPO
- 2019
- Employees
- 120
- HQ
- Florham Park, NJ, US
Price Chart
Valuation
- Market Cap
- $19.85M
- P/E
- -0.23
- P/S
- 0.75
- P/B
- -0.55
- EV/EBITDA
- -0.70
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 76.04%
- Op Margin
- -230.92%
- Net Margin
- -345.44%
- ROE
- 411.46%
- ROIC
- -151.11%
Growth & Income
- Revenue
- $26.55M · -51.03%
- Net Income
- $-91,800,000 · -58.57%
- EPS
- $-3.59 · -35.75%
- Op Income
- $-61,308,000
- FCF YoY
- -101.98%
Performance & Tape
- 52W High
- $4.35
- 52W Low
- $0.71
- 50D MA
- $1.14
- 200D MA
- $1.73
- Beta
- 0.45
- Avg Volume
- 203.55K
Get TickerSpark's AI analysis on CELU
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Dec 19, 25 | Barach Philip Alan | other | 1,204,819 |
| Jun 19, 26 | Barach Philip Alan | other | 839,160 |
| Dec 19, 25 | Barach Daniele Wolf | other | 1,204,819 |
| Jun 19, 26 | Barach Daniele Wolf | other | 839,160 |
| Dec 19, 25 | Philip & Daniele Barach Family Trust | other | 1,204,819 |
| Jun 19, 26 | Philip & Daniele Barach Family Trust | other | 839,160 |
| Apr 13, 26 | Brigido Stephen | other | 821 |
| Apr 13, 26 | Brigido Stephen | other | 268 |
| Apr 13, 26 | Brigido Stephen | other | 821 |
| Apr 13, 26 | Haines John R | other | 1,641 |
Our CELU Coverage
We haven't published any research on CELU yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate CELU Report →